AAAAAA
Results: 26-39/39
Authors:
Palmer, JR
Driscoll, SG
Rosenberg, L
Berkowitz, RS
Lurain, JR
Soper, J
Twiggs, LB
Gershenson, DM
Kohorn, EI
Berman, M
Shapiro, S
Rao, RS
Citation: Jr. Palmer et al., Oral contraceptive use and risk of gestational trophoblastic tumors, J NAT CANC, 91(7), 1999, pp. 635-640
Authors:
Gershenson, DM
Deavers, M
Diaz, S
Tortolero-Luna, G
Miller, BE
Bast, RC
Mills, GB
Silva, EG
Citation: Dm. Gershenson et al., Prognostic significance of p53 expression in advanced-stage ovarian serousborderline tumors, CLIN CANC R, 5(12), 1999, pp. 4053-4058
Authors:
Gershenson, DM
Citation: Dm. Gershenson, Contemporary treatment of borderline ovarian tumors, CANCER INV, 17(3), 1999, pp. 206-210
Authors:
Brewer, M
Gershenson, DM
Herzog, CE
Mitchell, MF
Silva, EG
Wharton, JT
Citation: M. Brewer et al., Outcome and reproductive function after chemotherapy for ovarian dysgerminoma, J CL ONCOL, 17(9), 1999, pp. 2670-2675
Authors:
Rose, PG
Blessing, JA
Gershenson, DM
McGehee, R
Citation: Pg. Rose et al., Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study, J CL ONCOL, 17(9), 1999, pp. 2676-2680
Authors:
Anderson, LD
Hudson, JM
Savary, CA
Fisk, B
Gershenson, DM
Ioannides, CG
Citation: Ld. Anderson et al., HER-2/neu peptide specificity in the recognition of HLA-A2 by natural killer cells, CANCER IMMU, 48(7), 1999, pp. 401-410
Authors:
Wolf, JK
Mills, GB
Bazzet, L
Bast, RC
Roth, JA
Gershenson, DM
Citation: Jk. Wolf et al., Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status, GYNECOL ONC, 75(2), 1999, pp. 261-266
Authors:
Wolf, JK
Kim, TE
Fightmaster, D
Bodurka, D
Gershenson, DM
Mills, G
Wharton, JT
Citation: Jk. Wolf et al., Growth suppression of human ovarian cancer cell lines by the introduction of a p16 gene via a recombinant adenovirus, GYNECOL ONC, 73(1), 1999, pp. 27-34
Authors:
Wolf, JK
Mullen, J
Eifel, PJ
Burke, TW
Levenback, C
Gershenson, DM
Citation: Jk. Wolf et al., Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary, GYNECOL ONC, 73(1), 1999, pp. 35-41
Authors:
Burger, RA
DiSaia, PJ
Roberts, JA
O'Rourke, M
Gershenson, DM
Homesley, HD
Lichtman, SM
Barnes, W
Moore, DH
Monk, BJ
Citation: Ra. Burger et al., Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer, GYNECOL ONC, 72(2), 1999, pp. 148-153
Authors:
Morris, M
Eifel, PJ
Lu, JD
Grigsby, PW
Levenback, C
Stevens, RE
Rotman, M
Gershenson, DM
Mutch, DG
Citation: M. Morris et al., Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer, N ENG J MED, 340(15), 1999, pp. 1137-1143
Authors:
Gershenson, DM
Morris, M
Burke, TW
Levenback, C
Wolf, J
Lee, JJ
Thall, PF
Atkinson, EN
Silva, EG
Wharton, JT
Citation: Dm. Gershenson et al., A Phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma, CANCER, 86(11), 1999, pp. 2291-2300
Authors:
Lin, PS
Gershenson, DM
Bevers, MW
Lucas, KR
Burke, TW
Silva, EG
Citation: Ps. Lin et al., The current status of surgical staging of ovarian serous borderline tumors, CANCER, 85(4), 1999, pp. 905-911
Authors:
Gershenson, DM
Citation: Dm. Gershenson, Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: Implications for ovarian cancer screening - Discussion, AM J OBST G, 180(4), 1999, pp. 925-927